Skip to main content



Comparing Biosimilar Growth in the US, Germany, and Switzerland

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article

Exciting Data for SLE: Plenaries from #ACR22

ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!

Read Article

Video Telehealth Willingness Increased During Pandemic

Nov 08, 2022

Americans’ willingness to use video telehealth has increased since the beginning of the COVID-19 pandemic, rising most sharply among Black Americans and people with less education, according to a new RAND Corporation study.

Following a representative survey panel of Americans from

Read Article
DLE discoid lupus

ACR Promotes CME on Lupus Clinical Trials Racial Disparities

Nov 02, 2022

The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/

Read Article

Can You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?

Nov 02, 2022

Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA). Now an open label study of ixekizumab (IXE) treated axSpA patients in remission has shown that the vast majority of IXE withdrawal patients who later flared were able to recapture

Read Article

Lack of Gender Equity in Academic Rheumatology

Nov 01, 2022

Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results

Read Article

Excessive Alcohol-Related Deaths in US Adults

Nov 01, 2022

Alcohol consumption is a leading preventable cause of death in the U.S.  A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to

Read Article
warning, caution

EMA Crack Down on JAK Inhibitors

Oct 31, 2022

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Read Article

Increasing Prevalence of RA, PsA and AS in the UK

Oct 25, 2022

Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Increasing Risk of Lupus Nephritis

Oct 25, 2022

Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.

Cases of incident LN

Read Article
RheumNow Podcast square

ACR Award Winners (10.21.2022)

Oct 21, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

  1. Vaccination Cut Long COVID Risk for Rheum Patients Patients with

Read Article
Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit billed, $12.14 generated in downstream revenues (infusions, labs, surgery). Cognitive specialists are undervalued!
RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Oct 07, 2022

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on

  1. Microbiome analyses of

Read Article

Physician Burnout Rising

Oct 06, 2022

The NY Times has reported results of a study showing that nearly two-thirds of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic.  These findings suggest that burnout rates amongst US doctors have risen to alarming levels.

Read Article (keep)

Women Doctors More Likely to Be Called By First Name in Patient Messages

Oct 05, 2022

Female physicians were more likely to be called by their first names in electronic medical record (EMR) patient portal messaging, researchers found.

In adjusted analyses, women doctors were more than twice as likely as their male counterparts to be addressed by their first name in

Read Article

Transitioning JIA to Adult Care is Problematic

Oct 04, 2022

Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood. This report of the Nordic experience shows that both pediatric and adulty rheumatologists need to develop "transition" practices; without such an approach considerable gaps in healthcare will befall these

Read Article

Causes of Death in Lupus

Oct 03, 2022

The California Lupus Surveillance Project has longitudinally followed included systemic lupus erythematosus (SLE) cases and shown that overall, the leading cause of death was cardiovascular disease (CVD), followed by rheumatic disease and hematologic/oncologic conditions.

Read Article

Opioid Crisis Costs USA $1.5 Trillion

Sep 29, 2022

Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.

Read Article
ACR20 Capitol

Rheumatology Leaders and Patient Advocates Convene on Capitol Hill

Sep 26, 2022

ACR members along with rheumatology patients gathered on Capitol Hill and urged federal lawmakers to support the HELP Copays Act, Safe Step Act, and Improving Seniors’ Timely Access to Care Act.

Read Article

ACR's State-by-State Report Cards for Rheumatic Disease

Sep 19, 2022

New report examines access, affordability, and activity and lifestyle factors in all 50 states and the District of Columbia, evaluating how easy it is to live with a rheumatic disease in your state. No state scored an "A" or "F", and only two states improved their 2018 grades.

Read Article

70% of Older Adults Report Joint Pain

Sep 14, 2022

Dr. Beth Wallace and colleagues at the University of Michigan surveyed a national sample of older adults (50–80 yrs) and found that 70% currently report experiencing joint pain and 60% reported being told by a health care professional that they have arthritis. 

Read Article

Doctor Appointment Wait TImes are Up

Sep 12, 2022

Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.

This is based on a 15 U.S. city survey of more than 1,000 physician offices - including family medicine, dermatology, obstetrics/

Read Article

ACR Questions Medicare Proposed Cuts to Critical Services Reimbursement by Cognitive Specialists

Sep 08, 2022

In comments submitted to the Centers for Medicare and Medicaid Services (CMS) in response to the CY 2023 Medicare Physician Fee Schedule and Quality Payment Program proposed rule, the American College of Rheumatology applauded proposals that would provide more flexibility and improve care

Read Article

Global Trends Informing the Future of Rheumatoid Arthritis

Sep 06, 2022

Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time. 

The article appears in Nature Reviews Rheumatology and discusses worldwide variance

Read Article
RheumNow Podcast square

Goofy But True

Sep 02, 2022

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on

  1. After historic drop in 2020 (COVID), life expectancy in USA dropped again,

Read Article